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and p44/42MAPK signaling, suppress the
expression of structural compo-
nents and cell adhesion molecules in
murine and human keratinocyte cultures.
Omori-Miyake et al. (2014) first
observed that IL-4 would suppress the
expression of Dsg1, Dsc1, keratin 1, and
keratin 10 at both mRNA and
protein levels in murine and human
cultured keratinocytes. The authors
confirmed that the regulation by IL-4
was dependent on IL-4 receptor-alpha
and STAT6.
Moreover, the suppression of expres-
sion of Dsg1, keratin 1, and keratin 10 by
IL-4 was prevented by the addition of an
MEK inhibitor, suggesting that the sup-
pression was regulated via p44/42MAPK
signaling. Addition of the p38MAPK inhi-
bitor did not alter the suppressed expres-
sion of Dsg1, keratin 1, or keratin 10 by
IL-4, suggesting that p38MAPK is not
responsible in this suppression. The sup-
pression of Dsc1 expression by IL-4 was
not prevented by the addition of the MEK
inhibitor, suggesting the important role of
STAT6 signaling in Dsc1 expression.
Similar suppressive effects were also
found by the addition of IL-13 in parallel
experiments. In contrast, the addition of
IL-5 did not cause a suppressive effect.
These results suggest that IL-4 and
IL-13 have important roles in the patho-
genesis of AD.
Omori-Miyake et al. (2014) also
examined mRNA expression levels of
keratins and desmosomal components
in IL-4 receptor-alpha chain–deficient
keratinocytes. No reduction in mRNA
expression for these proteins was
observed by the addition of IL-4 and
IL-13 in these deficient keratinocytes,
confirming that IL-4 and IL-13 exerted
their effects via the IL-4 receptor-
alpha chain.
Finally, the addition of IL-4 and IL-13
to cultured HaCaT cells led to cell
fragmentation through downregulation
of expression of Dsg1, Dsc1, keratin 1,
and keratin 10. The authors speculated
that AD may develop or be exacerbated
by the disruption of epidermal stability
owing to the suppression of structural
components and cell adhesion mole-
cules by Th2 cytokines.
This work is the first comprehensive
study of the role of Th2 cytokines on the
suppression of structural components
and cell adhesion molecules, leading
to reduced stability and integrity of
keratinocytes. It indicates that in addi-
tion to immunological and allergic
mechanisms, as well as filaggrin muta-
tion and tight junction–related changes
in the skin barrier, the stability and
integrity of the epidermis itself, which
are regulated by cytokines, may also
have important roles in AD.
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Dormant Melanomas or Changing
Nevi?
Giuseppe Argenziano1, Aimilios Lallas1, Caterina Longo1,
Elvira Moscarella1, Margherita Raucci1 and Iris Zalaudek1,2
The development of new primary melanomas in patients treated with
vemurafenib has been reported recently in a study by Perier-Muzet et al. The
primary outcome of the study was to describe the dermoscopic changes that
prompted excision of those melanomas. However, the crucial point raised by the
study is the large number of melanomas that were detected.
Journal of Investigative Dermatology (2014) 134, 1196–1198; doi:10.1038/jid.2013.512
The study by Perier-Muzet et al. (2014)
is an important contribution, one that
reports the largest series of second
primary melanomas in patients treated
with vemurafenib for advanced melano-
mas. The development of multiple
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squamous cell carcinomas is a well-
known phenomenon occurring in
patients treated with vemurafenib, but
the appearance of new primary melano-
mas in those patients has only recently
been reported.
From the same group of investigators,
Dalle et al., (2011) first described five
new early melanomas that developed in
four patients undergoing vemurafenib
treatment. Subsequently, Zimmer et al.,
(2012) described 12 new primary mela-
nomas detected in 11 of 19 patients
treated with vemurafenib. In the study
by Perier-Muzet et al. (2014) 14 second
primary melanomas were found in 9 of
42 patients treated with vemurafenib
over a mean follow-up period of about
7 months.
The intention of the investigators in
this study was to describe the dermo-
scopic changes that prompted excision of
the subsequent melanomas. Although
more than 1000 lesions (56% of the
monitored lesions) changed over time,
only 36 were excised. The criteria that
prompted excision were not quantita-
tively different than those occurring in
non-excised lesions. However, several
qualitative changes were found to be
associated more frequently in the excised
compared with non-excised lesions,
including changes in size, changes in
network morphology, and development
of new criteria such as pigmented
islands, dark areas, and globules.
On the basis of the assumption that
no melanomas were left untreated,
these dermoscopic characteristics
allowed a good performance in terms
of ‘‘number needed to excise’’ (2.6 nevi
excised to find 1 melanoma). This estab-
lished the efficiency of the method, i.e.,
digital dermoscopy, which is designed
specifically to detect early melanoma
while minimizing unnecessary excisions
(Salerni et al., 2013).
To our eye, the crucial point raised by
this study is, however, related to the
very high number of melanomas
detected in this and earlier cohorts.
The risk for a patient with melanoma
to develop a second primary melanoma
is about 5% (Moseley et al., 1979),
whereas in this study 21% of the
patients undergoing vemurafenib
treatment developed a second primary
lesion. A possible explanation suggested
by the authors was the following: ‘‘y
these melanomas were biologically
present yet dormant, and, moreover,
clinically undetectable before the
instauration of therapy, and therefore
only revealed by the wild type BRAF
paradoxical activation by specific
V600E BRAF blockers, then picked-up
by repeated follow-up’’.
In our opinion, an alternative expla-
nation should be considered, namely:
at least some of the melanocytic lesions
classified as melanoma in patients
treated with vemurafenib might be
preexisting nevi that mimic melanoma
histopathologically due to drug-induced
activation. The development of clinical
and histopathologic features of melano-
mas is a well-known phenomenon that
may also occur, for example, in nevi
after an acute UV irradiation (Tronnier
and Wolff, 1995) or in regrowing nevi
after incomplete removal (Kornberg and
Ackerman, 1975).
There are, indeed, data in the study
by Perier-Muzet et al. (2014) that point
towards this alternative explanation.
First, not only the excised melanomas
but also a substantial number of nevi
(56%) changed in these patients. Also,
as pointed out by Haenssle et al. (2012),
a variety of dermoscopic changes can
be observed in melanocytic nevi of
patients treated with vemurafenib.
On one hand, nevi may involute,
especially those originally showing
a papillomatous surface, clinically, and
a predominant globular pattern,
dermoscopically. On the other hand,
preexisting nevi may increase in
size and become atypical, especially
those that are clinically flat and
dermoscopically reticular. Finally, new
small reticular nevi may develop as
well. Notably, papillomatous globular
nevi harbor activating BRAF mutations
at much higher frequency than flat
reticular nevi may develop. Thus, it is
reasonable to consider that globular
nevi with oncogenic BRAF mutations
will involute during treatment with
vemurafenib, whereas the new and
growing reticular nevi are those
carrying wild-type BRAF (Zalaudek
et al., 2011). Apart from the latter
speculation, it is a matter of fact that
vemurafenib treatment induced changes
not only in excised lesions that are
histopathologically classified as mela-
noma, but also in a great proportion of
melanocytic nevi in these patients.
A second important issue lies in the
fact that the 14 melanomas found by
Perier-Muzet et al. (2014) were all
present before treatment was initiated.
The authors did not report whether
nevus remnants were histopathologi-
cally found in those melanomas. Thus,
we can presumably exclude the
possibility of new melanomas develop-
ing within preexisting nevi after treat-
ment initiation. In other words, those
melanomas were not induced but just
revealed by vemurafenib. If this is
true, it means that 21% of all patients
with resected primary melanoma do
eventually harbor ‘‘dormant’’ addition-
al melanomas that will not be disco-
vered unless unmasked by vemurafenib.
Although theoretically possible, this
scenario seems less plausible than the
more simple hypothesis that preexisting
nevi may have acquired morphologic
features mimicking melanoma due to
drug-induced activation.
In summary, further research is war-
ranted to clarify to what extent patients
treated with vemurafenib are at higher
risk for developing new primary melano-
mas than those who do not undergo this
treatment. This is obviously not a trivial
issue for dermatologists and dermato-
pathologists, as changing melanocytic
lesions occurring under vemurafenib
treatment need to be differentiated and
eventual melanomas diagnosed as early
as possible. To this end, while these
BRAF inhibitors are now being entered
into large-scale trials in the adjuvant
setting for patients with melanoma, the
Clinical Implications
 Changing melanocytic lesions during vemurafenib treatment should be
identified, and those that are melanomas diagnosed as soon as possible.
 Digital dermoscopy during follow-up examinations is an efficient method
of detecting early melanomas while minimizing unnecessary excisions.
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study by Perier-Muzet et al. highlights
the need for careful sequential skin
examinations, including dermoscopy
and digital monitoring of these patients.
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Indomethacin to the Rescue of
TRAIL-Resistant Melanomas
Rajasekharan Somasundaram1 and Meenhard Herlyn1
Patients with melanomas develop resistance to both conventional- and targeted-
therapy drugs. Promising clinical responses with immune checkpoint reagents
have resulted in renewed interest in the use of biological therapies, although only
subsets of individuals are known to respond to these reagents. Tse et al. now
report on the use of indomethacin, an anti-inflammatory drug, to sensitize
therapy-resistant melanoma cells.
Journal of Investigative Dermatology (2014) 134, 1198–1199; doi:10.1038/jid.2014.1
Melanoma is an aggressive form of skin
cancer with few treatment options. Mel-
anomas are comprised of heterogeneous
subtypes having distinct molecular sig-
natures (Finn et al., 2012). Due to this
complexity, single-agent therapies for
melanomas remain largely unsuccess-
ful. This is because most patients with
metastatic melanoma quickly develop
resistance to both conventional (dacar-
bazine and temozolomide) and targeted
therapies (vemurafenib, dabrafenib
(BRAF inhibitors) and trametinib (MEK
inhibitor)). Even though targeted-therapy
drugs have shown dramatic reductions
in tumor burden when compared with
conventional chemotherapeutic agents,
clinical responses are often relatively
short-lived (Flaherty et al., 2013). In
contrast to targeted-therapy drugs,
clinical responses to immune check-
point reagents (anti-CTLA4 and anti-
PD1) are more durable and long
lasting (Pennock et al., 2011; Hamid
et al., 2013). However, therapy respon-
ses in patients with good clinical
outcome depend on the existence of
sufficient numbers of pre-sensitized anti-
melanoma T cells in the circulation or in
tumor infiltrates. Thus, only subsets of
patients respond to anti-CTLA4 or anti-
PD1 (McDermott and Atkins, 2013). The
targeted-therapy drug, vemurafenib, is
known paradoxically to activate T cells,
increase infiltration of these cells and
upregulate melanoma-associated anti-
gens on tumor cells, resulting in impro-
ved effectiveness by melanoma-reactive
T cells (Cooper et al., 2013). This has
led to combination-therapy trials com-
prising vemurafenib and anti-CTLA4.
Early observations suggest that the
combination-therapy trials are accom-
panied by serious side effects of skin and
liver toxicities (Ribas et al., 2013). The
reasons for these toxicities are poorly
understood; however, T cells reacting to
normal tissue antigens could be one of
the major issues in such trials. Thus,
there is a need to find additional rea-
gents that target tumor survival directly.
Many tumor types, including melanomas,
evade therapies due to a defective ability
of cancer cells to undergo apoptosis.
Thus, targeting apoptotic pathways may
improve drug sensitivities and minimize
toxicities that are frequently associated
with the other therapies.
Apoptosis is a normal physiological
process by which cells undergo pro-
grammed cell death in response to
intrinsic (mitochondrial-mediated) or
extrinsic (tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-
mediated) signals (Hersey and Zhang,
2001). Auto-reactive immune cells,
virus-infected cells and DNA-defective
or dysfunctional cells are eliminated by
apoptotic phenomena to maintain tissue
integrity. Apoptosis is generally
accompanied by three main events: (a)
activation of caspase, a primary driver of
apoptosis; (b) DNA and protein degra-
dation; and (c) changes in membrane
morphology leading to phagocytic
elimination by scavenger cells.
Activation of caspase is dependent on
intrinsic mitochondrial–mediated or
classical extrinsic TRAIL– or death
receptor (DR)–mediated signaling
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